Phase I Trial of BAY1251152 for Advanced Blood Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-17

Study Completion Date

2018-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia

NCT02345382

Leukemia

COMPLETED PHASE1

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

NCT03404726

Leukemia

TERMINATED PHASE1

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

NCT02366949

Medical Oncology

COMPLETED PHASE1

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

NCT03127735

Leukemia, Myeloid, Acute

COMPLETED PHASE1

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

NCT00084916

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) +12 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Biomarker-enriched advanced hematological neoplasms

Group Type EXPERIMENTAL

BAY1251152

Intervention Type DRUG

Weekly infusion of BAY1251152 in 21-day cycles.

Arm 2

Other selected advanced hematological neoplasms

Group Type EXPERIMENTAL

BAY1251152

Intervention Type DRUG

Weekly infusion of BAY1251152 in 21-day cycles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAY1251152

Weekly infusion of BAY1251152 in 21-day cycles.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged ≥18 years
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks
* Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol
* Patients with confirmed advanced hematological malignancies
* Negative serum pregnancy test
* Women and men of reproductive potential must agree to use highly effective contraception when sexually active.
* Ability to understand and the willingness to sign a written informed consent.
* Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN)
* Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN

Exclusion Criteria

* Presence of active/uncontrolled central nervous system involvement
* History of clinically significant cardiac disease; uncontrolled hypertension
* Left ventricular ejection fraction (LVEF) \< 45%
* Allogeneic stem cell transplant within 100 days before first dose of study drug
* Known history of human immunodeficiency virus (HIV) infection
* Chronic or active hepatitis B or C, requiring antiviral therapy
* Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study
* Serious, uncontrolled infection
* Unresolved chronic toxicity \> grade 1 from prior therapy
* Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No